ストックスクリーナーアプリを入手
11.73
1.21%
0.14
アフターアワーズ：
11.75
0.02
+0.17%
前日終値:
$11.59
開ける：
$11.64
24時間の取引高:
1.34M
Relative Volume:
0.83
時価総額：
$1.31B
収益：
$577.74M
当期純損益:
$-149.78M
株価収益率:
-8.3786
EPS:
-1.4
ネットキャッシュフロー:
$-78.21M
1週間 パフォーマンス:
+5.39%
1か月 パフォーマンス:
-30.14%
6か月 パフォーマンス:
-47.82%
1年 パフォーマンス:
-37.97%
1日の値動き範囲:
$11.46
$11.86
1週間の範囲:
$10.87
$11.99
52週間の値動き範囲:
$10.87
$34.13
Novocure Ltd Stock (NVCR) Company Profile
NVCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
11.73 | 1.30B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
131.75 | 225.01B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.17 | 154.32B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.91 | 144.71B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.02 | 117.85B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.26 | 45.90B | 5.69B | 1.41B | 577.90M | 6.95 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2024-12-02 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-10-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 開始されました | SVB Securities | Outperform |
| 2023-07-31 | アップグレード | Evercore ISI | Underperform → In-line |
| 2023-06-07 | アップグレード | Wedbush | Underperform → Neutral |
| 2023-05-16 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-01-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-11-29 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-08 | 開始されました | Loop Capital | Buy |
| 2022-02-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2022-01-03 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-07-01 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-14 | ダウングレード | Wedbush | Neutral → Underperform |
| 2021-01-25 | 繰り返されました | Piper Sandler | Overweight |
| 2020-09-23 | 開始されました | Northland Capital | Outperform |
| 2020-09-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | ダウングレード | Truist | Buy → Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Perform |
| 2020-05-01 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-04-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2020-03-05 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-07-29 | アップグレード | SunTrust | Hold → Buy |
| 2019-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-07-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Hold |
| 2018-11-02 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 開始されました | Evercore ISI | Outperform |
| 2018-04-18 | 繰り返されました | Mizuho | Buy |
| 2018-02-23 | 繰り返されました | Mizuho | Buy |
| 2017-05-24 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 繰り返されました | Wedbush | Outperform |
| 2016-01-19 | 開始されました | Barclays | Underweight |
| 2015-12-02 | 開始されました | Deutsche Bank | Hold |
すべてを表示
Novocure Ltd (NVCR) 最新ニュース
Is NovoCure's (NVCR) Rising Active Patient Count Reshaping Its Investment Case? - simplywall.st
Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR) - Yahoo Finance
Statistical indicators supporting NovoCure Limited’s strengthFree Watchlist for Low Risk High Return - Newser
Novocure stock hits 52-week low at 10.88 USD By Investing.com - Investing.com Nigeria
Novocure stock hits 52-week low at 10.88 USD - Investing.com
NovoCure's Optune Study for Glioblastoma Treatment: A Potential Game-Changer in the Market - AInvest
Is NovoCure Limited trending in predictive chart modelsAsset Growth Pattern and Return Summary - Newser
Short interest data insights for NovoCure LimitedTechnical Confirmation System with Signal Alerts - Newser
Detecting price anomalies in NovoCure Limited with AILow Drawdown Stock Screener with Analysis - Newser
NovoCure’s Pivotal Study on Optune® for Glioblastoma: A Market Game-Changer? - TipRanks
Real time scanner hits for NovoCure Limited explainedAI Short-Term Gain Forecast with Data - Newser
How institutional ownership impacts NovoCure Limited stockFree Triple Digit Return Stock Predictions - Newser
How strong is NovoCure Limited company’s balance sheetRapid wealth multiplication - Jammu Links News
What are analysts’ price targets for NovoCure Limited in the next 12 monthsCapitalize on emerging market sectors - Jammu Links News
How volatile is NovoCure Limited stock compared to the marketBreakthrough profit margins - Jammu Links News
Is NovoCure Limited stock poised for growthAnnual Market Behavior and Sector Summary - Newser
Chief Financial Officer of NovoCure Christoph Brackmann Buys 339% More Shares - simplywall.st
NovoCure (NVCR) Sales Rise but Losses Deepen—Is Profitability or Growth the Bigger Priority? - simplywall.st
NovoCure (NASDAQ:NVCR) Shares Up 9.3% After Insider Buying Activity - Defense World
Novocure’s Earnings Call: Clinical Successes & Cautious Optimism - TipRanks
NovoCure CFO Makes a Bold Move: Christoph Brackmann Purchases $231,800 Worth of Stock - AInvest
NovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain Ahead - Seeking Alpha
Will NovoCure Limited stock benefit from AI tech trendsWeekly Entry Signal Based Forecast Tool - Newser
Multi asset correlation models including NovoCure LimitedFree Low Risk Buy Zone Opportunity Watch - Newser
Why NovoCure Stock Is Cratering Today - Mitrade
NovoCure Limited (NASDAQ:NVCR) Q2 2025 Earnings Call Transcript - Insider Monkey
Does NovoCure Limited show high probability of reboundSafe Entry Strategy with High Win Rate - Newser
What are NovoCure Limited company’s key revenue driversDiscover undervalued stocks before they soar - Jammu Links News
Top 3 Health Care Stocks That May Explode In July - inkl
Wells Fargo & Company Reaffirms Equal Weight Rating for NovoCure (NASDAQ:NVCR) - Defense World
NovoCure Q2 2025 Earnings Highlights: Revenue Growth Amidst Challenges - AInvest
NovoCure Second Quarter 2025 Earnings: Beats Expectations - simplywall.st
NovoCure: Q2 Earnings Snapshot - Norwalk Hour
NovoCure Limited 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NVCR) - Seeking Alpha
Bank of New York Mellon Corp Grows Stake in NovoCure Limited (NASDAQ:NVCR) - Defense World
Wells Fargo Downgrades NovoCure (NVCR) with Significant Price Ta - GuruFocus
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $38 - 富途牛牛
NovoCure Limited Stock Analysis and ForecastBreakneck growth rates - Autocar Professional
NovoCure Ltd (NVCR) Q2 2025 Earnings Call Highlights: Revenue Gr - GuruFocus
Novocure stock hits 52-week low at 14.17 USD By Investing.com - Investing.com Australia
Novocure Ltd (NVCR) 財務データ
収益
当期純利益
現金流量
EPS
1.74%
0.24%
大文字化:
|
ボリューム (24 時間):